NCT02079649View on ClinicalTrials.gov

Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Allergic Conjunctivitis
Interventions
DRUG

AL-53817 Ophthalmic Solution, 0.1%

DRUG

AL-78843 Ophthalmic Solution, 0.03%

DRUG

Dexamethasone Ophthalmic Suspension, 0.1%

DRUG

AL-53817 Vehicle

Inactive ingredients used for masking purposes

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY